
The World Health Organisation (WHO) reported elevated resistance levels to GSK's HIV drug, dolutegravir, surpassing trial rates. Resistance ranged from 3.9% to 8.6%, reaching 19.6% in those transitioning to dolutegravir-containing antiretroviral therapy (ART). The WHO emphasized routine surveillance to understand resistance patterns. GSK supported further surveillance. The findings underscore the importance of monitoring HIV drug resistance globally.
Like
Save
Share